Precision BioSciences (DTIL) Tops Q2 EPS by 40c; Reports Cash and Cash Equivalents of $160.5M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DTIL Hot Sheet
Join SI Premium – FREE
Precision BioSciences (NASDAQ: DTIL) reported Q2 EPS of ($0.19), $0.40 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $24 million versus the consensus estimate of $6.02 million.
For earnings history and earnings-related data on Precision BioSciences (DTIL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Precision BioSciences (DTIL) Tops Q3 EPS by 56c
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
